Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
24 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/24/3193375/0/en/Aquestive-Therapeutics-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html
05 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/05/3181904/0/en/Aquestive-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177236/0/en/Aquestive-Therapeutics-to-Attend-2025-ACAAI-Annual-Meeting.html
27 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/27/3174425/0/en/Aquestive-Therapeutics-to-Report-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights-on-November-5-and-Host-Conference-Call-on-November-6-at-8-00-a-m-ET.html
08 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/08/3163180/0/en/Aquestive-Therapeutics-Broadens-Patent-Estate-for-Anaphylm.html
26 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/26/3139129/0/en/Aquestive-Therapeutics-to-Participate-in-Upcoming-September-Investor-Conferences.html
Drugs in Development
Details:
The proceeds from the offering will be used to advance the launch & commercialization of Anaphylm (epinephrine) for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: RTW Investments
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 14, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : RTW Investments
Deal Size : $85.0 million
Deal Type : Public Offering
Aquestive Announces Pricing of $85 Million Underwritten Offering of Common Stock
Details : The proceeds from the offering will be used to advance the launch & commercialization of Anaphylm (epinephrine) for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Undisclosed
August 14, 2025
Details:
The proceeds from the financing will be used to advance the launch & commercialization of Anaphylm (epinephrine) for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: RTW Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 14, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : RTW Investments
Deal Size : $75.0 million
Deal Type : Financing
Aquestive Announces $75M Strategic Funding Agreement with RTW
Details : The proceeds from the financing will be used to advance the launch & commercialization of Anaphylm (epinephrine) for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Undisclosed
August 14, 2025
Details:
Anaphylm (epinephrine) is a non-selective alpha and beta adrenergic agonist being investigated in pediatric for allergic reaction.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Shares Positive PK Data and Completes NDA for Anaphylm
Details : Anaphylm (epinephrine) is a non-selective alpha and beta adrenergic agonist being investigated in pediatric for allergic reaction.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Inapplicable
April 01, 2025
Details:
Libervant (diazepam) is a GABA-A receptor; anion channel positive allosteric modulator. It is approved for the acute treatment of patients with epilepsy between 2 to 5 years of age.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Brand Name: Libervant
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Therapeutics Receives Orphan Drug Exclusivity for Libervant®
Details : Libervant (diazepam) is a GABA-A receptor; anion channel positive allosteric modulator. It is approved for the acute treatment of patients with epilepsy between 2 to 5 years of age.
Product Name : Libervant
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 19, 2024
Details:
Anaphylm (epinephrine) sublingual film has the potential to be the first and only non-invasive, oral epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Reaffirms Anaphylm NDA Submission After FDA Feedback
Details : Anaphylm (epinephrine) sublingual film has the potential to be the first and only non-invasive, oral epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Inapplicable
December 02, 2024
Details:
Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is being investigated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Reports Positive Results for Anaphylm in Oral Allergy Syndrome
Details : Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is being investigated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Inapplicable
October 24, 2024
Details:
Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is being investigated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 14, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Comments on FDA Approval of Non-Injection Epinephrine Product for Anaphylaxis
Details : Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is being investigated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Inapplicable
August 14, 2024
Details:
DESF is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypersensitivity.
Lead Product(s): DESF,Epinephrine
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2024
Lead Product(s) : DESF,Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics Study of DESF in Adults with Oral Allergy Syndrome
Details : DESF is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypersensitivity.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 30, 2024
Details:
Anaphylm (epinephrine) sublingual film has the potential to be the first and only non-invasive, oral epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 25, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Therapeutics Reports Positive Data for Anaphylm™ Sublingual Film
Details : Anaphylm (epinephrine) sublingual film has the potential to be the first and only non-invasive, oral epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Inapplicable
July 25, 2024
Details:
Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is indicated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Anaphylm
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aquestive Reports Positive Anaphylm™ Study Data for Epinephrine Sublingual Film
Details : Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is indicated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Product Name : Anaphylm
Product Type : Hormone
Upfront Cash : Inapplicable
June 25, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
ABOUT THIS PAGE
Share 
